A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs LY 3002813 (Primary) ; LY 3002813 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly
- 21 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Jul 2017.
- 21 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 Jul 2017.
- 25 May 2017 Planned End Date changed from 28 Apr 2017 to 1 May 2017.